CytomX Therapeutics (NASDAQ: CTMX) is a clinical-stage biotechnology company that develops conditionally activated antibody-drug conjugates (ADCs) and other therapeutics for cancer treatment. Revenue is derived from non-refundable license payments, milestone payments, and reimbursements for research and development expenses under collaboration and license agreements with pharmaceutical partners. For FY2025, total revenue was $76.2 million, down from $138.1 million in FY2024, with Bristol Myers Squibb ($41.9M), Astellas ($17.9M), Regeneron ($6.5M), and Amgen ($9.8M) as the primary revenue sources. The company's lead wholly owned asset is Varseta-M, a conditionally activated ADC targeting EpCAM-expressing epithelial cancers including colorectal cancer, armed with a camptothecin-based topoisomerase-1 inhibitor payload. CX-801 (IFNα2b) is a second internal program. The company executed a 40% workforce reduction in early 2025 and terminated the CX-2029 program in Q1 2025. Sean A. McCarthy serves as CEO and Chairman, with Christopher W. Ogden as CFO.

Revenue model

Collaboration and licensing revenue from pharmaceutical partners, comprising upfront non-refundable license payments, milestone payments, and R&D expense reimbursements recognized over the estimated research service period using an input method tied to FTE hours incurred.

Products and services

Varseta-M: conditionally activated ADC targeting EpCAM-expressing epithelial cancers (including colorectal cancer), armed with CAMP59, a camptothecin-based topoisomerase-1 inhibitor payload. CX-801: IFNα2b program. CX-904 (EGFRxCD3): bispecific program, largely wound down by FY2025. PROBODY platform: proprietary conditional activation technology applied across ADC and other therapeutic modalities.

Customers and end markets

Pharmaceutical and biopharmaceutical company partners as direct customers: Bristol Myers Squibb ($41.9M, FY2025), Astellas ($17.9M, FY2025), Amgen ($9.8M, FY2025), Regeneron ($6.5M, FY2025), and Moderna ($31K, FY2025). End market is oncology, specifically solid tumors including colorectal cancer and hematologic malignancies.

Value-chain role

Preclinical and clinical-stage drug developer providing proprietary conditional activation platform technology and co-developing cancer therapeutics under collaboration agreements. Does not manufacture or commercialize products independently; relies on partners for downstream development, manufacturing, and commercialization.

Geographic exposure

Headquartered in the United States. Subject to EU GDPR and UK GDPR for international data activities, indicating some international clinical operations, but no geographic revenue breakdown is disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-16

Industry: Pharmaceutical Preparations Peers: Bioxytran Inc Elutia Inc Candel Therapeutics Inc Decibel Therapeutics, Inc. Galectin Therapeutics Inc Immunic Inc Insight Molecular Diagnostics Inc vTv Therapeutics Inc